Comprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: Focusing on Asians and Asian countries

Serum testosterone improves the accuracy of Prostate Health Index for the detection of prostate cancer

(2014) Frank Friedersdorff et al.   CLINICAL BIOCHEMISTRY

Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen

(2014) Kazuto Ito et al.   International Journal of Clinical Oncology

Stability of [−2]Pro-PSA in Whole Blood and Serum: Analysis for Optimal Measurement Conditions

(2014) Tsukasa Igawa et al.   JOURNAL OF CLINICAL LABORATORY ANALYSIS

Fusion Between TMPRSS2 and ETS Family Members (ERG, ETV1, ETV4) in Prostate Cancers from Northern China

(2013) Jian-Jiang Wang et al.   Asian Pacific Journal of Cancer Prevention

Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy

(2013) Atsushi Ochiai et al.   BJU INTERNATIONAL

Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS

(2013) Massimo Lazzeri et al.   BJU INTERNATIONAL

Serum Isoform [−2]proPSA Derivatives Significantly Improve Prediction of Prostate Cancer at Initial Biopsy in a Total PSA Range of 2–10 ng/ml: A Multicentric European Study

(2013) Massimo Lazzeri et al.   EUROPEAN UROLOGY

The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4–10 ng/mL

(2013) C. F. Ng et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

The impact of baseline [−2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort

(2013) Hiromi Hirama et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Head-to-Head Comparison of Prostate Health Index and Urinary PCA3 for Predicting Cancer at Initial or Repeat Biopsy

(2013) Vincenzo Scattoni et al.   JOURNAL OF UROLOGY

PCA3 Molecular Urine Test as a Predictor of Repeat Prostate Biopsy Outcome in Men with Previous Negative Biopsies: A Prospective Multicenter Clinical Study

(2013) Marc C. Gittelman et al.   JOURNAL OF UROLOGY

Early Detection of Prostate Cancer: AUA Guideline

(2013) H. Ballentine Carter et al.   JOURNAL OF UROLOGY

Prostate Cancer Risk Profiles of Asian-American Men: Disentangling the Effects of Immigration Status and Race/Ethnicity

(2013) Daphne Y. Lichtensztajn et al.   JOURNAL OF UROLOGY

Assays for Prostate Cancer

(2013) Jens Hansen et al.   Molecular Diagnosis & Therapy

Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml

(2013) Matteo Ferro et al.   PLoS One

Differences in prostate cancer grade, stage, and location in radical prostatectomy specimens from United States and Japan

(2013) Hiroyuki Takahashi et al.   PROSTATE

[-2]proPSA is an early marker for prostate cancer aggressiveness

(2013) I Heidegger et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Correlation of UrineTMPRSS2:ERGandPCA3to ERG+ and Total Prostate Cancer Burden

(2012) Allison Young et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers

(2012) Matteo Ferro et al.   CLINICA CHIMICA ACTA

Multicenter Evaluation of [-2]Proprostate-Specific Antigen and the Prostate Health Index for Detecting Prostate Cancer

(2012) C. Stephan et al.   CLINICAL CHEMISTRY

Comparative Assessment of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG Gene Fusion with the Serum [-2]Proprostate-Specific Antigen-Based Prostate Health Index for Detection of Prostate Cancer

(2012) C. Stephan et al.   CLINICAL CHEMISTRY

The Role of Genetic Markers in the Management of Prostate Cancer

(2012) Atish D. Choudhury et al.   EUROPEAN UROLOGY

Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer

(2012) Gisele H.J.M. Leyten et al.   EUROPEAN UROLOGY

Serum Index Test %[-2]proPSA and Prostate Health Index are More Accurate than Prostate Specific Antigen and %fPSA in Predicting a Positive Repeat Prostate Biopsy

(2012) Massimo Lazzeri et al.   JOURNAL OF UROLOGY

Association of [−2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer

(2012) Jeffrey J. Tosoian et al.   JOURNAL OF UROLOGY

Development and Internal Validation of a Prostate Health Index Based Nomogram for Predicting Prostate Cancer at Extended Biopsy

(2012) Giovanni Lughezzani et al.   JOURNAL OF UROLOGY

Diagnostic Performance of PCA3 to Detect Prostate Cancer in Men with Increased Prostate Specific Antigen: A Prospective Study of 1,962 Cases

(2012) E. David Crawford et al.   JOURNAL OF UROLOGY

Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration

(2012) Stacy Loeb et al.   JOURNAL OF UROLOGY

Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer

(2012) Jean-Nicolas Cornu et al.   PROSTATE

Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy

(2012) Sisto Perdonà et al.   PROSTATE

Beyond PSA: The Next Generation of Prostate Cancer Biomarkers

(2012) J. R. Prensner et al.   Science Translational Medicine

Longitudinal Changes of Benign Prostate-specific Antigen and [−2]Proprostate-specific Antigen in Seven Years in a Community-based Sample of Men

(2012) Thomas Rhodes et al.   UROLOGY

Diagnostic significance of [−2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0–10.0 ng/mL range

(2012) Kazuto Ito et al.   WORLD JOURNAL OF UROLOGY

Cost-effectiveness of Prostate Health Index for prostate cancer detection

(2011) Michael B. Nichol et al.   BJU INTERNATIONAL

Prostate-Specific Antigen (PSA) Isoform p2PSA Significantly Improves the Prediction of Prostate Cancer at Initial Extended Prostate Biopsies in Patients with Total PSA Between 2.0 and 10 ng/ml: Results of a Prospective Study in a Clinical Setting

(2011) Giorgio Guazzoni et al.   EUROPEAN UROLOGY

Preoperative Prostate-Specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer

(2011) Giorgio Guazzoni et al.   EUROPEAN UROLOGY

A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range

(2011) William J. Catalona et al.   JOURNAL OF UROLOGY

Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA

(2011) S. A. Tomlins et al.   Science Translational Medicine

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer

(2011) Simpa S. Salami et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

ProPSA and Diagnostic Biopsy Tissue DNA Content Combination Improves Accuracy to Predict Need for Prostate Cancer Treatment Among Men Enrolled in an Active Surveillance Program

(2011) Sumit Isharwal et al.   UROLOGY

A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [-2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness

(2010) L. J. Sokoll et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection

(2010) Flip H. Jansen et al.   EUROPEAN UROLOGY

PCA3 gene expression in prostate cancer tissue in a Chinese population: Quantification by real-time FQ-RT-PCR based on exon 3 of PCA3

(2010) Zhihua Tao et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population

(2010) Mo Shen et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Detection of TMPRSS2-ETS Fusions by a Multiprobe Fluorescence in Situ Hybridization Assay for the Early Diagnosis of Prostate Cancer

(2010) Qi-Peng Sun et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in Populations at Risk: Validation in the Placebo Arm of the Dutasteride REDUCE Trial

(2010) Sheila M.J. Aubin et al.   JOURNAL OF UROLOGY

[-2]Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer From Benign Disease in a Prospective Prostate Cancer Screening Study

(2010) Brian V. Le et al.   JOURNAL OF UROLOGY

ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples

(2010) Yohei Miyagi et al.   MODERN PATHOLOGY

TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african-american and japanese patients

(2010) Cristina Magi-Galluzzi et al.   PROSTATE

ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice

(2009) Scott A. Tomlins et al.   EUROPEAN UROLOGY

Proprostate-specific antigen: Its usefulness in the era of multiple-core prostate biopsy

(2009) Mai Miyakubo et al.   INTERNATIONAL JOURNAL OF UROLOGY